State

US Virgin Islands product recalls

73,824 recalls have nationwide distribution and so reach US Virgin Islands. 178 additional recalls listed US Virgin Islands specifically in their distribution scope.

What the numbers show

Total: 178
Critical: 12
Severe: 39
Most recent: 2026-10-21

Of the 178 recalls naming US Virgin Islands we have scored against our rubric, 12 (7%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 39 (22%) are Severe.

Which agencies issued them

These figures cover only the 178 recalls whose distribution notice names US Virgin Islands specifically. The 73,824 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

54176–54200 of 74002

SevereFDA (Drugs)·D-568-2015·2015-04-29
Attix Pharmaceuticals Recalls Cefixime API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cefixime active pharmaceutical ingredient (API) due to potential penicillin cross-contamination from inadequate facility separation.
Product
Cefixime active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-750-2015·2015-04-29
Leflunomide API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Leflunomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Leflunomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-787-2015·2015-04-29
Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Methscopolamine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-640-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxorubicin HCI Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Doxorubicin HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Doxorubicin HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-641-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxycycline HCI Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxycycline HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxycycline HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-783-2015·2015-04-29
Attix Pharmaceuticals Recalls Methazolamide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Methazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Devices)·Z-1513-2015·2015-04-29
CSA Medical truFreeze Console Cryosurgical Unit Recalled for Excess Liquid Nitrogen Delivery
CSA Medical is recalling 82 truFreeze Console cryosurgical units because they may deliver excessive liquid nitrogen, posing risks of stricture, scarring, bradycardia, or pneumothorax.
Product
CSA Medical truFreeze Console- Cryosurgical Unit Cryogenic Surgical Device Model: CC3-01
Category
Medical Device
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-564-2015·2015-04-29
Attix Pharmaceuticals Recalls Carboxymethyl Dextran Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Carboxymethyl Dextran active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Carboxymethyl Dextran active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-610-2015·2015-04-29
Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dantrolene Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Dantrolene Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-744-2015·2015-04-29
Attix Pharmaceuticals Recalls Ketotifen Fumarate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Ketotifen Fumarate active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Ketotifen Fumarate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-845-2015·2015-04-29
Attix Pharmaceuticals Recalls Piroxicam Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling piroxicam active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Piroxicam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-943-2015·2015-04-29
Attix Pharmaceuticals Recalls Trichlormethiazide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Trichlormethiazide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Trichlormethiazide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-677-2015·2015-04-29
Fluconazole API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Fluconazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Fluconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-801-2015·2015-04-29
Attix Pharmaceuticals Recalls Mirtazapine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Mirtazapine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Mirtazapine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-619-2015·2015-04-29
Attix Pharmaceuticals Recalls Demeclocycline HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Demeclocycline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Demeclocycline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-901-2015·2015-04-29
Attix Pharmaceuticals Recalls Sodium Starch Glycolate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Sodium Starch Glycolate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Sodium Starch Glycolate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-743-2015·2015-04-29
Attix Pharmaceuticals Recalls Ketorolac Tromethamine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Ketorolac Tromethamine active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Ketorolac Tromethamine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-814-2015·2015-04-29
Attix Pharmaceuticals Recalls Natamycin API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Natamycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.
Product
Natamycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-637-2015·2015-04-29
Attix Pharmaceuticals Recalls Domperidone API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Domperidone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Domperidone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-821-2015·2015-04-29
Attix Pharmaceuticals Recalls Ofloxacin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Ofloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Ofloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-877-2015·2015-04-29
Attix Pharmaceuticals Recalls Reserpine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling reserpine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Reserpine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-661-2015·2015-04-29
Attix Pharmaceuticals Recalls Ethinyl Estradiol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Ethinyl Estradiol active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Ethinyl Estradiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-893-2015·2015-04-29
Sildenafil Citrate Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Sildenafil Citrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Sildenafil Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-827-2015·2015-04-29
Attix Pharmaceuticals Recalls Oseltamivir Phosphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Oseltamivir Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Oseltamivir Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-705-2015·2015-04-29
Attix Pharmaceuticals Recalls Histamine Diphosphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Histamine Diphosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Histamine Diphosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide